Received May 28, 2026
Reports are unverified and do not show that a vaccine caused an event. Full disclaimer
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| VARZOS | ZOSTER (SHINGRIX) | GLAXOSMITHKLINE BIOLOGICALS | 5 | — | — |
| VARZOS | ZOSTER (SHINGRIX) | GLAXOSMITHKLINE BIOLOGICALS | 4 | — | — |
| VARZOS | ZOSTER (SHINGRIX) | GLAXOSMITHKLINE BIOLOGICALS | 3 | — | — |
| VARZOS | ZOSTER (SHINGRIX) | GLAXOSMITHKLINE BIOLOGICALS | 2 | — | — |
Extra doses; Extra doses; Extra doses; Drug dose administration interval too long; This non-serious case was reported by a pharmacist via call center representative and described the occurrence of drug dose administration interval too long in a 66-year-old female patient who received Herpes zoster (Shingrix) solution for injection for prophylaxis. Co-suspect products included Herpes zoster (Shingrix) for prophylaxis. Previously administered products included Shingrix (received first dose on 13-JAN-2020). On 16-FEB-2026, the patient received the 5th dose of Shingrix. On 04-SEP-2020, an unknown time after receiving Shingrix, the patient experienced drug dose administration interval too long (Verbatim: Drug dose administration interval too long). On 17-JUN-2022, the patient experienced extra dose administered (Verbatim: Extra doses). On 04-AUG-2023, the patient experienced extra dose administered (Verbatim: Extra doses). On 16-FEB-2026, the patient experienced extra dose administered (Verbatim: Extra doses). The outcome of the drug dose administration interval too long, extra dose administered, extra dose administered and extra dose administered were not applicable. Additional Information: GSK Receipt Date:21-MAY-2026 The reporter stated that one of their patients had received five doses of Shingrix. The batch number was not provided upon follow up with the reporter.